CCR Antagonist

CCR Antagonists (105):

Cat. No.	Product Name	Effect	Purity

HY-117621

PF-04634817	Antagonist	98.87%
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy.

HY-117621A

PF-04634817 succinate	Antagonist	99.50%
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy.

HY-P4191

Met-RANTES (human)	Antagonist
Met-RANTES (human) is the antagonist for CCR1 and CCR5. Met-RANTES (human) inhibits chemokines human MIP-1α and MIP-1β with IC₅₀ of 5 and 2 nM. Met-RANTES (human) reduces bone destruction and ameliorates rats adjuvant-induced arthritis (AIA).

HY-112792A

(1S)-CCR2 antagonist 1	Antagonist	98.03%
(1S)-CCR2 antagonist 1 is a left-handed chiral body of CCR2 antagonist 1 (HY-112792). CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a K_i of 2.4 nM.

HY-17450

Aplaviroc	Antagonist
Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC₅₀s of 0.1-0.4 nM for HIV-1_Ba-L, HIV-1_JRFL and HIV-1_MOKW.

HY-162495

IDOR-1117-2520	Antagonist	99.94%
IDOR-1117-2520 is a potent and selective antagonist of CCR6. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC₅₀ = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC₅₀ = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 can be used for research of autoimmune diseases.

HY-15450

INCB 3284 dimesylate	Antagonist	≥98.0%
INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

HY-125836

CCR4 antagonist 2	Antagonist
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.

HY-114193

CCR1 antagonist 6	Antagonist
CCR1 antagonist 6 (compound 16q) is a chemokine receptor 1 (CCR1) antagonist, with an IC₅₀ of 3 nM.

HY-114194

CCR1 antagonist 7	Antagonist
CCR1 antagonist 7 (compound 16r) is a chemokine receptor 1 (CCR1) antagonist, with an IC₅₀ of 4 nM.

HY-115874

BMS-753426	Antagonist
BMS-753426 is a potent and orally bioavailable antagonist of CCR2.

HY-114097A

CCR1 antagonist 11 hydrochloride	Antagonist
CCR1 antagonist 11 hydrochloride (A1B1) is an orally active CCR1 antagonist with the IC₅₀ values of 0.03 μM, 0.58 μM and 0.32 μM for hCCR1, mCCR1 and rCCR1, respectively. CCR1 antagonist 11 hydrochloride can be used in the study of rheumatoid arthritis and other related inflammatory diseases.

HY-15544

CCR1 antagonist 10	Antagonist
CCR1 antagonist 10 (example 1) is a potent and orally active CCR1 antagonist. CCR1 antagonist 10 inhibits ¹²⁵I-MIP-1α binding to THP-1 cell membranes with an K_i value of 2.3 nM.

HY-13004R

Maraviroc (Standard)	Antagonist
Maraviroc (Standard) is the analytical standard of Maraviroc. This product is intended for research and analytical applications. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.

HY-14230

INCB9471	Antagonist
INCB9471 is a potent, selective and orally active CCR5 antagonist. INCB9471 shows anti-HIV-1 activity.

HY-B0155

Vicriviroc	Antagonist
Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.

HY-12079

CP-481715	Antagonist
CP-481715 is a potent, reversible and selective CCR1 antagonist with a K_d of 9.2 nM for human CCR1. CP-481715 is >100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related chemokine receptors. CP-481715 has the potential for rheumatoid arthritis and other inflammatory diseases research.

HY-14388

PF-232798	Antagonist
PF-232798 is an orally active CCR5 antagonist with anti-HIV effects.

HY-13245B

(Rac)-PF-4136309	Antagonist	≥98.0%
(Rac)-PF-4136309 is an isoform of PF-4136309 (HY-13245), which is a potent, selective, and orally bioavailable CCR2 antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-50084

CCR2-RA	Antagonist
CCR2-RA is a allosteric antagonist of chemokine (C-C motif) receptor 2 (CCR 2), and it can be used in cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.